<DOC>
	<DOCNO>NCT01979393</DOCNO>
	<brief_summary>This study aim investigate drug call Cabozantinib belongs family drug effect tumour growth , blood supply , invasion spread . Therefore , want find whether take cabozantinib treatment surgery chemotherapy effective safe patient respond stable disease chemotherapy . All participant receive 4-6 cycle standard chemotherapy . Those stabilization response standard chemotherapy split 2 group ( cabozantinib placebo ) .</brief_summary>
	<brief_title>IRCI Gynae Sarcomas , High Grade Uterine Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Locally advanced : newly diagnose HGUS advanced disease ( stage III stage IV ) residual disease primary surgery Metastatic : diagnosed disease relapse local treatment primary tumor least 18 year old write informed consent Central pathological confirmation : Histological evidence HGUS Nonprogressive patient ( CR , PR , SD ) end first line treatment ( standard chemotherapy consist 4 6 cycle anthracyclines alone combination ifosfamide ) WHO/ECOG performance status 02 Adequate organ bone marrow function within 3 day prior first dose study treatment ( Cabozantinib/placebo ) Clinically normal cardiac function Women child bear potential must negative serum/urine pregnancy test within 3 day prior first dose study treatment adequate birth control measure low grade sarcoma ( ESS &amp; leiomyosarcoma ) , leiomyosarcoma ( intermediate &amp; high grade ) , carcinosarcoma , adenosarcoma , rhabdomyosarcoma ( alveolar embryonal ) soft tissue Primitive Neuroectodermal Tumors uterus/cervix . contraindication cabozantinib able swallow retain oral tablet plan use chemotherapy , radiation therapy , radionuclide treatment , small molecule tyrosine kinase inhibitor hormonal therapy , investigational agent ( Cabozantinib/placebo ) treatment period concurrent uncompensated hypothyroidism thyroid dysfunction within 7 day first dose study treatment patient poorly control hypertension define baseline blood pressure &gt; 150/90 patient suffer cerebrovascular accident time past , patient suffer transient ischemic attack past 6 month , patient suffer deep venous thrombosis ( DVT ) pulmonary embolism past 6 month Gastrointestinal disorder patient radiographic evidence cavitating pulmonary lesion ( ) patient tumor contact , invade encase major blood vessel patient evidence tumor invade GI tract evidence active bleeding bleed diathesis hemoptysis â‰¥ 0.5 teaspoon ( 2.5ml ) red blood within 3 month first dose study treatment sign indicative pulmonary hemorrhage within 3 month first dose study treatment clinicallysignificant gastrointestinal bleeding within 6 month first dose study treatment prior major surgery trauma within 6 week prior first dose study drug wound , fracture , ulcer completely heal concurrent plan treatment strong inhibitor inducer cytochrome P450 3A4/5</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Locally advanced</keyword>
	<keyword>stage III</keyword>
	<keyword>stage IV</keyword>
	<keyword>residual disease primary surgery</keyword>
	<keyword>newly diagnose HGUS</keyword>
	<keyword>Metastatic</keyword>
</DOC>